◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocksAZN › Revenue

AstraZeneca PLC (AZN) Revenue 2006–TTM

DATA UPDATED 2026-07-19

AstraZeneca PLC annual revenue for fiscal TTM was $60.4 billion, an increase of 2.9% from $58.7 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

AZN Annual Revenue

Revenue (annual)TTM → 2026-03-312025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-31
Total Revenue$60.4B$58.7B$54.1B$45.8B$44.4B$37.4B$26.6B$24.4B$22.1B$22.5B$23.0B$24.7B$26.5B$25.8B$28.0B$33.6B$33.3B$32.8B$31.6B$29.6B$26.5B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AZN Quarterly Revenue

Revenue (quarterly)2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-30
Total Revenue$15.3B$15.5B$15.2B$14.5B$13.6B$14.9B$13.6B$12.9B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

More AZN metrics: Gross Profit · Operating Income · Net Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding

All AZN financial statements → Interactive AZN charts →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.